Found: 10
Select item for more details and to access through your institution.
25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 21, p. 11869, doi. 10.3390/ijms222111869
- By:
- Publication type:
- Article
Repurposing Navitoclax to block SARS‐CoV‐2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 10, p. 1, doi. 10.1002/jmv.29145
- By:
- Publication type:
- Article
SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 3, p. 1, doi. 10.1002/jmv.28641
- By:
- Publication type:
- Article
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 1, p. 1, doi. 10.1002/jmv.28143
- By:
- Publication type:
- Article
A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 4, p. N.PAG, doi. 10.3390/v14040655
- By:
- Publication type:
- Article
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 3, p. 549, doi. 10.3390/v14030549
- By:
- Publication type:
- Article
Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic recombinant EK1 peptide.
- Published in:
- Cell Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41421-023-00631-2
- By:
- Publication type:
- Article
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.
- Published in:
- Signal Transduction & Targeted Therapy, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41392-021-00712-2
- By:
- Publication type:
- Article
Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha).
- Published in:
- 2021
- By:
- Publication type:
- Letter
Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha).
- Published in:
- 2021
- By:
- Publication type:
- Letter